Cargando…
Endoscopic Lung Volume Reduction: Review of the EMPROVE and LIBERATE trials
Endoscopic lung volume reduction is now included in the guidelines for treatment in severe chronic obstructive pulmonary disease. Since December 2018, 2 valve systems have been approved by the US Food and Drug Administration (FDA). To date, there is no head-to-head trial comparing both valve systems...
Autores principales: | Nada, Khaled M., Nishi, Shawn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930786/ https://www.ncbi.nlm.nih.gov/pubmed/33718791 http://dx.doi.org/10.1016/j.mayocpiqo.2020.09.009 |
Ejemplares similares
-
Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System: Still a Great Need to “EMPROVE”
por: Jain, Avinash, et al.
Publicado: (2020) -
Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial
por: Criner, Gerard J., et al.
Publicado: (2019) -
Reply to Jain et al.: Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System: Still a Great Need to “EMPROVE”
Publicado: (2020) -
Review of lung sealant technologies for lung volume reduction in pulmonary disease
por: Milenkovic, Branislava, et al.
Publicado: (2018) -
Impact of Endoscopic Lung Volume Reduction on Right Ventricular Myocardial Function
por: Pizarro, Carmen, et al.
Publicado: (2015)